Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.
Frequently asked questions
What sector does Pure Biologics Spólka Akcyjna (PUR) operate in?
Pure Biologics Spólka Akcyjna belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pure Biologics Spólka Akcyjna (PUR) current stock price?
As of the latest data, Pure Biologics Spólka Akcyjna stock price is PLN 3.14, with a previous close of PLN 3.14.
What is Pure Biologics Spólka Akcyjna (PUR) current market capitalization?
Pure Biologics Spólka Akcyjna market cap is approximately 38.45 million.
What is Pure Biologics Spólka Akcyjna (PUR) Earnings Per Share (EPS)?
The trailing EPS is -PLN 1.68.
What is Pure Biologics Spólka Akcyjna (PUR) EBITDA?
Pure Biologics Spólka Akcyjna EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.67 million.
Does Pure Biologics Spólka Akcyjna (PUR) pay dividends?
No. Pure Biologics Spólka Akcyjna does not pay a dividend.
What is Pure Biologics Spólka Akcyjna (PUR) beta (volatility) score?
Pure Biologics Spólka Akcyjna has a beta of 0.213, indicating lower volatility than the overall market.